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Research
Fetuses, newborns, infants, and adolescents 
are populations uniquely susceptible to bio-
chemical insult from environ  mental chemi-
cals. Although some of these toxicities may 
be evident immediately, some exposures that 
take place during early critical periods of 
development can result in subtle alterations 
that are delayed in expression. Hence, at the 
time of clinical manifestation in adulthood, 
the original chemical effector may no longer 
be measurable.
One such environmental chemical is bis-
phenol A (BPA), a chemical originally devel-
oped for use as a synthetic estrogen and now 
one of the highest-volume chemicals produced 
in the world (Burridge 2003; Welshons et al. 
2006). BPA is used in the manufacture of poly-
carbonate plastics and resins, which are com-
monly used in the packaging of canned foods 
and in beverage bottles. BPA may be ingested 
by humans, as it reportedly leaches from the 
lining of food and soda cans, (Biles et al. 1997; 
Brotons et al. 1994), poly  carbonate bottles 
(Kang et al. 2006), and dental sealants (Olea 
et al. 1996). As a consequence of this wide-
spread opportunity for exposure, an estimated 
95% of Americans tested, including young 
girls, show detectable concentrations of BPA 
in their urine (Calafat et al. 2005; Wolff et al. 
2007). Concern regarding the potential role 
of BPA in breast cancer is supported by ani-
mal studies showing the developing mammary 
gland as one of the tissues targeted by prenatal 
BPA exposure (Durando et al. 2007). Markey 
et al. (2001) showed that mice exposed in utero 
to 250 µg BPA/kg body weight (BW) via 
osmotic pumps had a significantly greater num-
ber of ductal and alveolar structures rela  tive to 
the control group on postnatal day (PND) 
180. Similarly, Murray et al. (2007) reported 
the development of ductal hyper  plasia in CD-1 
mice on PND50 and PND95 after prenatal 
exposure to 2.5, 25, 50, and 1,000 µg BPA/kg   
BW/day. In another study, Moral et al. (2008) 
showed that adult offspring exposed pre-
natally via dams treated orally with 250 µg 
BPA/kg BW/day had modifications of the 
mammary gland architecture, mainly in the 
number of undifferentiated epithelial struc-
tures of the tissue. A previous study from 
our laboratory (Jenkins et al. 2009) showed 
that prepubertal exposure to BPA increased 
7,12-dimethylbenz(a)anthracene (DMBA)-
induced mammary carcino  genesis in Sprague-
Dawley CD rats on PND50. Therefore, our 
next goal was to determine if in utero expo-
sure to BPA would elicit a similar response in 
the mammary gland after carcinogenic insult. 
In the initial phase of the study, we investi-
gated the effects of prenatal BPA exposure 
[25 or 250 µg/kg BW/day on gestation day 
(GD) 10–GD21] on tumori  genesis and pro-
tein expression at PND50 in rats. For the sec-
ond phase of the study, we investigated the 
effects of prenatal BPA exposure (250 µg/kg   
BW/day) on tumori  genesis and protein expres-
sion at PND100. Differential protein expres-
sion patterns induced by prenatal exposure 
to BPA in the mammary gland on PND50 
and PND100 suggest a possible mechanism 
of action for the increased susceptibility of 
the mammary gland to chemically induced 
carcino  genesis on PND100.
Materials and Methods
Chemicals. We obtained antibodies to phos-
pho-c-proto-oncogene serine/threonine-protein 
kinase (phospho-c-Raf), phospho-insulin-like 
growth factor 1 receptor (phospho-IGF-1R), 
receptor tyrosine-protein kinase erbB-2 (phos-
pho-ErbB2), phospho-serine/threonine-protein 
kinase Akt (phospho-Akt), and glyceralde-
hyde-3-phosphate dehydrogenase (GADPH) 
from Cell Signaling (Danvers, MA). Steroid 
receptor coactivator 1 (SRC-1), SRC-2/ 
transcriptional intermediary factor 2 (SRC-2/
TIF2), and SRC-3/amplified in breast can-
cer-1 protein antibodies were purchased from 
Becton, Dickinson and Company (Franklin 
Lakes, NJ). Epidermal growth factor receptor 
(EGFR), estrogen receptor-α (ER-α), proges-
terone receptor (PR), and B-cell lymphoma 2 
(Bcl-2) antibodies were purchased from R&D 
Systems (Minneapolis, MN); and extra  cellular 
signal-regulated kinase 1/2 (phospho-ERK 
1/2) antibodies were from Promega (Madison, 
WI). All other chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO).
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Ba c k g r o u n d: Bisphenol A (BPA) is a ubiquitous environmental chemical with reported endocrine-
disrupting properties.
oB j e c t i v e: Our goal in this study was to determine whether prenatal exposure to BPA predisposes 
the adult rat mammary gland to carcinogenesis.
Me t h o d s : Pregnant rats were treated orally with 0, 25, or 250 µg BPA/kg body weight (BW) 
from gestation day (GD) 10 to GD21. For tumori  genesis experiments, prenatally exposed female 
offspring received a single gavage of 7,12-dimethylbenz(a)anthracene (DMBA; 30 mg/kg BW) on 
postnatal day (PND) 50, or PND100.
re s u l t s: Prenatal exposure of the dam to 250 µg BPA/kg BW combined with a single exposure 
of female offspring to DMBA on PND100, but not on PND50, significantly increased tumor 
incidence while decreasing tumor latency compared with the control group. Prenatal exposure of 
the dam to 250 µg BPA/kg BW, in the absence of DMBA to the female offspring, increased cell 
proliferation and elicited differential effects at the protein level at PND100 compared with PND50. 
Differentially regulated proteins in the mammary gland included estrogen receptor-α, progesterone 
receptor-A, Bcl-2 , steroid receptor coactivators, epidermal growth factor receptor, phospho-insulin-
like growth factor 1 receptor, and phospho-Raf.
co n c l u s i o n s: Our study demonstrates that oral prenatal exposure to BPA increases mammary can-
cer susceptibility in offspring and shifts the window of susceptibility for DMBA-induced tumori-
genesis in the rat mammary gland from PND50 to PND100. These changes are accompanied 
by differential effects of prenatal BPA exposure on the expression of key proteins involved in cell 
proliferation.
key w o r d s : bisphenol A, cell proliferation, endocrine disruptors, mammary cancer, susceptibility. 
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Animals. Animal studies were conducted 
in accordance with the University of Alabama 
at Birmingham Guidelines for Animal Use 
and Care. Animals were treated humanely 
and with regard for alleviation of suffering.   
Adult male and female Sprague-Dawley 
CD rats (Charles River, Raleigh, NC) were 
housed in a temperature-  controlled environ-
ment (22 ± 2°C) with a 12-hr dark-light cycle 
(lights on between 0800 and 2000 hours). 
The initial experiments were designed to 
determine the potential of prenatal exposure 
to BPA to alter a) the endocrine system dur-
ing post  natal develop  ment; b) ER-α, SRC, 
and growth factor signaling protein levels in 
the mammary gland; and c) susceptibility 
to chemically induced mammary cancer at 
PND50 in the resulting offspring. For this, 
pregnant rats (a minimum of 30/group) were 
gavaged with BPA at 25 µg/kg BW/day (low 
dose) or 250 µg/kg BW/day (high dose), or 
an equivalent volume of sesame oil (control 
group) on GD10–GD21. Two additional 
groups of animals were also exposed pre  natally 
to high-dose BPA (250 µg/kg BW) and con-
trol treatments to investigate a potential shift 
in the period of susceptibility for chemically 
induced mammary cancer at PND100 in the 
resulting offspring. 
Animals were bred, and female rats were 
observed for the presence of sperm. Once 
sperm positive (noted as GD0), pregnant 
females were housed individually in poly-
propylene cages (BPA-free) with glass water 
bottles, fed the phyto  estrogen-free AIN-93G 
(growth) diet (Dyets Inc, Bethlehem, PA), and 
randomly assigned to a treatment group. On 
the day of birth (designated as PND0), off-
spring were sexed, and litters were culled to 
10 females per lactating dam. The female off-
spring were weaned on PND21 and continued 
on AIN-93G diet until PND70, when they 
were switched to AIN-93M (mature) diet. On 
PND50 ± 1 and PND100 ± 2, two sets (n = 8/
treatment group) of identically treated rats were 
killed in the estrous phase. The fourth abdomi-
nal mammary glands were rapidly dissected 
from live ketamine/xylazine-anesthetized ani-
mals prior to euthanasia. One set of mammary 
glands was frozen in liquid nitrogen and stored 
at –80°C until assayed via immuno  blotting. 
The contra  lateral gland was fixed in formalin 
for paraffin embedding. For each treatment 
group on both PND50 and PND100, mam-
mary gland samples from individual rats 
randomly selected from each litter of each treat-
ment group (8–10 rats/treatment group) were 
used for either immuno  blotting or paraffin 
embedding. Because chemical treatment of a 
dam during prenatal exposure results in a single 
exposure group per treatment, one offspring in 
each litter was treated as a single observation. 
Tumorigenesis experiments. For tumori-
genesis experiments, one female offspring from 
each litter was given a single gavage of 30 mg 
DMBA/kg BW on PND50 or PND100. This 
DMBA dose routinely results in a low number 
of mammary tumors in Sprague-Dawley rats 
and allows chemicals that pre  dispose for mam-
mary cancer to increase the number of mam-
mary adeno  carcinomas (Brown et al. 1998; 
Jenkins et al. 2009). On PND50, we treated 
31 control, 29 low-dose BPA, and 33 high-
dose BPA offspring (each from a separate lit-
ter) with DBMA; on PND100, 30 control 
and 28 high-dose BPA offspring were treated 
with DBMA. Animals were palpated twice 
weekly to monitor tumor development; data 
were recorded on palpable tumor latency, 
location, and multiplicity. Animals under-
went necropsy at 12 months of age or when 
the tumor burden exceeded 10% of BW. All 
tumors and gross lesions were dissected out and 
embedded in paraffin for pathological evalua-
tion. Coded slides were classified by a board- 
certified pathologist (I.A.E.) as to tumor type, 
tissue of origin, and degree of invasiveness. 
Histopathologic charac  teriza  tion of mammary 
neoplastic lesions included carcinoma grade, 
proliferation index, and malignancy evalua-
tions, as described by Meyer et al. (2005).
Estrous cyclicity. We monitored estrous 
cyclicity of female offspring for 22 days, 
starting at 4 months of age. Vaginal smears 
obtained daily from lavage fluid (collected by 
flushing the female’s vagina with phosphate-
buffered saline) were examined under a light 
microscope. The stage of the estrous cycle 
was determined based on vaginal cytology, as 
described by Everett (1989). We determined 
the number of cycles, number of days in 
estrus, and the cycle length. 
Immunoblotting. Immuno  blotting was 
performed on six to eight biologi  cal samples 
per treatment group, each sample derived 
from only one rat randomly selected from 
separate litters per treatment group, as pre-
viously described by Rowell et al. (2005), 
with modifications. Briefly, whole mam-
mary glands were ground in liquid nitrogen 
and homogenized in RIPA lysis buffer (Pierce 
Biotechnolgy, Rockford, IL). After homogeni-
za  tion, the samples were centrifuged for 20 min 
at 16,000 × g at 4°C. Equal protein content 
(40 µg) was loaded onto precast SDS Tris-
HCl poly  acrylamide gels (Bio-Rad, Hercules, 
CA). Proteins were wet-transferred to a nitro-
cellulose membrane overnight. The membrane 
was then blocked at room temperature, and 
the primary antibody was added and incubated 
overnight at 4°C. The secondary antibody and 
chemilume (Pierce Biotechnology) were added, 
and protein expression was visualized using 
film exposures. Densitometry patterns were 
assessed using Quantity One (Bio-Rad). We 
used Kaleidoscope Precision Plus Protein and 
Pre-stained SDS-PAGE Broad Range standards 
(Bio-Rad) to identify the protein of interest.
Cell proliferation. Tissue blocks were sec-
tioned at 5 µm onto glass slides. The slides 
were deparaffinized and rehydrated through 
a series of xylene and graded alcohol washes. 
Slides were boiled in citrate buffer for 15 min, 
incubated in hydrogen peroxide, blocked, and 
incubated in Ki-67 antibody (Dako, Glostrup, 
Denmark) overnight in a humidified chamber. 
After incubating the slides in the secondary 
antibody, we used the ImmPRESS kit (Vector 
Laboratories, Burlingame, CA) to determine 
antigen localiza  tion. Positively stained cells 
were visualized by incubating the slides with 
3,3´-diaminobenzidine (DAB) and counter-
stained with hematoxylin. Slides were dehy-
drated with graded alcohols, cleared with 
xylene, and mounted with a glass coverslip. We 
used six biologically distinct samples derived 
from individual litters and counted a mini-
mum of three ductal structures per slide. Cell 
prolifera  tion was identified as intense nuclear 
staining for Ki-67 protein. 
Apoptosis assay. We determined the rate of 
apoptosis using the ApopTag Plus Peroxidase 
In Situ Apoptosis Detection kit (Chemicon 
International, Billerica, MA) according to the 
manufacturer’s protocol. Cells that stained 
positive with DAB and exhibited morpholog-
ical charac  teris  tics of apoptosis were counted 
as positive. We evaluated five biologically dis-
tinct samples per treatment and counted a 
minimum of three terminal ductal structures 
per slide, for a total of ≥ 3,000 cells counted 
per treatment group. 
Statistical methods. The time to first 
tumor (latency) and time to sacrifice (tumor 
burden ≥ 10% of BW) were analyzed using 
the LIFETEST and LIFEREG procedures in 
SAS (SAS Institute Inc., Cary, NC). Survival 
functions were first estimated for each group 
using the Kaplan-Meier method and com-
pared across the groups using the Wilcoxon 
log-rank test and parametrically using survival 
regression analysis (Collette 2003). Animals 
that had not developed a tumor by the end of 
the study or were sacrificed before the end of 
the study were censored, and the end of study 
or sacrifice times were treated as censoring 
times. Tumor multiplicity was analyzed by 
the Cochran-Armitage trend test.
For cell proliferation and apoptosis, we 
used the values for stained versus unstained 
cells to construct a contingency table. Western 
blots were tested for equality of variance using 
a two-sample F-test, and the appropriate 
(assuming equal or unequal variance) two-
sample t-test was used. p-Values ≤ 0.05 were 
considered statistically significant.
Results
To evaluate dose response, we treated pregnant 
rats with 0, 25, or 250 µg BPA/kg BW on 
GD10–GD21. These BPA exposures did not 
significantly alter body weights of 2-, 7-, 14-, Betancourt et al.
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21-, 35-, 50-, and 100-day-old female offspring 
(data not shown). Similarly, prenatal exposure 
to BPA did not significantly alter the time to 
vaginal opening [32.5 ± 0.3, 34.4 ± 0.3, and 
32.6 ± 0.3 days (mean ± SE) for the zero-, 
low-, and high-dose BPA groups, respectively]. 
Serum concentrations of 17β-estradiol from 
50-day-old female offspring were not signifi-
cantly different from controls (11.0 ± 1.2, 
12.2 ± 2.3, and 14.5 ± 2.5 pg/mL for the 
zero-, low-, and high-BPA doses, respectively). 
Likewise, serum progesterone concentrations 
were not significantly different from controls 
(11.8 ± 2.1, 11.5 ± 1.2, and 9.4 ± 1.3 ng/mL   
for the zero-, low-, and high-BPA doses, 
respectively). Evaluation of estrous cyclicity 
of adult female offspring did not show signifi-
cant changes from either BPA dose (data not 
shown).
PND50 DMBA treatment and induced 
mammary carcino  genesis. Using the well- 
established chemically induced mammary can-
cer model, we treated female rats with DMBA 
on day 50, because this age has been shown 
to be optimum to induce mammary cancer 
in Sprague-Dawley rats (Russo et al. 1979; 
Welsch 1985). Palpating for mammary tumors, 
we found no significant difference for average 
time to first tumor for rats exposed prenatally 
to sesame oil only (controls), or to 25 µg or 
250 µg BPA/kg BW (mean ± SE, 109 ± 11 
days, 116 ± 14, 106 ± 14, respectively). At 
time of necropsy, we found no significant dif-
ference in tumor multiplicity (2.94 ± 0.48, 
2.38 ± 0.42, and 2.88 ± 0.40 tumors/rat 
exposed to 0, 25, and 250 µg BPA/kg BW, 
respectively) after DMBA treatment at day 50.
Differential protein expression. We pre-
viously reported that the pre  natal high BPA 
dose (250 µg/kg BW) resulted in the maxi-
mum number of modulated genes (Moral et al. 
2008) and proteins (Betancourt et al. 2010) 
at day 100 compared with day 50; therefore, 
we focused our mechanism of action studies 
on mammary glands of rats exposed pre  natally 
to 0 and 250 µg BPA/kg BW at those two 
ages. ER-α was significantly down-regulated 
at PND50 (p = 0.002), but up-regulated at 
PND100 (p = 0.042) after prenatal BPA expo-
sure (Figure 1). The expression of two down-
stream targets of ER (PR and Bcl-2) on both 
PND50 and PND100 were analyzed as indica-
tors of ER action. On PND50, both PR-A and 
Bcl-2 were significantly decreased (p = 0.003 
and p = 0.023, respectively) rela  tive to controls. 
On PND100, Bcl-2 was significantly increased 
(p = 0.01), and PR-A showed a non  significant 
increase (p = 0.09) (Figure 1).
Because one important factor influenc-
ing transcriptional activity of ER-α is the 
quantity of coregulators present in a given 
tissue, we determined protein levels of the 
Figure 1. Western blot analysis of ER-α, PR-A, and 
Bcl-2 in mammary glands of (A) 50-day-old and 
(B) 100-day-old rats exposed prenatally to 250 µg 
BPA/kg BW or an equal volume of sesame oil (con-
trols). Values represent mean density ± SE as a 
percentage of the control, with densitometry val-
ues for controls set to 100; n = 6–8 samples per 
group. Insets are representative immuno  blots for 
each protein per treatment. 
*p < 0.05 compared with corresponding controls. 
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Figure 2. Western blot analysis of SRC-1, SRC-2, 
and SRC-3 in mammary glands of (A) 50-day-old 
and (B) 100-day-old rats exposed prenatally to 
250 µg BPA/kg BW or an equal volume of sesame 
oil (controls). Values represent mean density ± SE 
as a percentage of the control, with densitometry 
values for controls set to 100; n = 6–8 samples per 
group. Insets are representative immuno  blots for 
each protein per treatment. 
*p < 0.05 compared with corresponding controls. 
200
150
100
50
0
200
150
100
50
0
SRC-3 SRC-2 SRC-1
SRC-3 SRC-2 SRC-1
* * *
*
P
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
P
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
PND50
Control
BPA
PND100
Figure 3. Western blot analysis of EGFR, phospho-IGF-1R, phospho-c-Raf, phospho-ERK 1/2, phospho-
ErbB2, and phospho-Akt in mammary glands of (A) 50-day-old and (B) 100-day-old rats exposed prenatally 
to 250 µg BPA/kg BW or an equal volume of sesame oil (controls). Values represent mean density ± SE as 
a percentage of the control, with densitometry values for controls set to 100; n = 6–8 samples per group. 
Insets are representative immuno  blots for each protein per treatment. 
*p < 0.05 compared with corresponding controls. 
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steroid receptor coactivators SRC-1, -2, and 
-3 (Figure 2). On PND50, only SRC-3 was 
significantly increased (p = 0.05). However, 
on PND100, all members of the SRC fam-
ily up-regulated (SRC-1, p = 0.003; SRC-2, 
p = 0.002; and SRC-3, p = 0.002). In addi-
tion, because pre  natal BPA exposure has been 
shown to increase cell proliferation in the 
mammary gland of the post  natal rat (Durando 
et al. 2007), we meas  ured key growth factor 
receptors and downstream signaling molecules 
(Figure 3). At PND100, BPA significantly 
increased expression of EGFR (p = 0.0132), 
phospho-IGF-1R (p = 0.007), phospho-c-Raf 
(p = 0.029), phospho-ERKs 1/2 (p = 0.030), 
phospho-ErbB2 (p = 0.039), and phospho-Akt 
(p = 0.017). However, on PND50, prenatal 
BPA exposure significantly up-regulated only 
phospho-ErbB2 (p = 0.018), phospho-ERK 
1/2 (p = 0.005), and phospho-Akt (p = 0.016).
Cell proliferation and apoptosis. Because 
of the significant changes in protein expres-
sion on PND100 in offspring with prenatal 
BPA exposure, we also investigated cell prolif-
eration and apoptosis in mammary glands at 
PND100. We found increased Ki-67 expres-
sion in the epithelial cells, but not the stroma, 
of mammary tubular ducts of 100-day-old 
rats prenatally exposed to BPA 250 (p < 0.05) 
(Figure 4) compared with controls. However, 
prenatal BPA exposure did not alter apop-
tosis in the mammary glands of these rats 
(p = 0.85) (data not shown).
PND100 DMBA treatment and induced 
mammary carcinogenesis. Because prenatal 
BPA exposure affected more signaling path-
ways in the mammary glands of PND100 
rats than of PND50 rats, our next step was to 
investigate whether those effects could translate 
to differences in the susceptibility of the mam-
mary gland to carcinogenesis on PND100 as 
opposed to PND50. To test this hypothesis, 
we treated female offspring exposed in utero 
to either sesame oil (control group) or BPA 
250 µg/kg BW with DMBA by a single gav-
age on PND100. Tumor incidence was sig-
nificantly increased in the BPA group (83.3%) 
versus the control group (53.6%) (p = 0.022), 
and there was a non  significant increase in 
tumor multiplicity [2.53 ± 0.55 vs. 1.96 ± 0.53 
(mean ± SE) in BPA-exposed and control ani-
mals, respectively; p = 0.07] (Figure 5). Female 
offspring exposed in utero to BPA 250 µg/kg 
BW also showed significantly decreased tumor 
latency (p = 0.012) compared with the control 
group (Figure 5C) after DBMA exposure on 
PND100. In addition, we classified a signifi-
cantly greater proportion of DMBA-induced 
mammary tumors as grade II (according to the 
Bloom-Richardson system) in BPA-exposed 
animals (9 of 20 tumors; 45%) versus control 
animals (3 of 13 tumors; 23%) (p = 0.0484). 
A single tumor from each animal was ran-
domly selected for histopathological analysis.
Figure 4. Cell proliferation in mammary glands of 100-day-old rats prenatally exposed to 250 µg BPA/kg BW 
or an equal volume of sesame oil (controls). (A) Ki-67 expression as an indicator of cell proliferation. Ducts 
from six biologically distinct samples (n = 6) were analyzed per treatment; magnification, 40×; bar = 100 µm. 
(B) Contingency table of cell proliferation data. (C) Ki-67 labeling index values (mean ± SE) as a percentage 
of the control group.
*p < 0.05 compared with controls.
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Discussion
The primary aim of this study was to determine 
if prenatal BPA exposure would predispose the 
adult rat mammary gland to carcino  genesis and 
if the protein signature could provide an insight 
into the possible targets of BPA in the mam-
mary gland. We choose the DMBA-induced 
mammary cancer model in Sprague-Dawley 
rats because there is similarity in ontogeny of 
mammary gland development and morphol-
ogy in rats and humans (Russo et al. 1990). 
DMBA-induced mammary cancer displays 
pathology similar to human breast cancer, 
including a common site of origin and a simi-
lar pattern of tumor development (McCormick 
and Moon 1965; Murad and von Haam 1972; 
Russo et al. 1977), and mammary cancers can 
be reproducibly induced with a high frequency 
in this model. In studies of cancer causation or 
chemo  prevention, the standard protocol for 
administering DMBA is at day 50, because 
this is within the period (days 40–60) of high 
mitotic index in the terminal ductal structures 
of rats (Russo et al. 1983; Welsch 1985). Using 
this protocol, we found no signifi  cant differ-
ence in tumor multiplicity or tumor latency 
in rats exposed prenatally to either of the BPA 
doses (25 and 250 µg/kg BW) after DMBA 
exposure on PND50. Based on previous evi-
dence suggesting differences in the mechanism 
of action of BPA at different ages (Betancourt 
et al. 2010; Moral et al. 2008), we suspected 
that the window of susceptibility for DBMA-
induced mammary cancer might be shifted 
from day 50 to day 100 after prenatal BPA 
exposure. Consequently, we found that 
DMBA treatment at PND100 resulted in a 
significantly higher incidence of mammary 
tumors in rats exposed prenatally to BPA. In 
addition, relative to control animals, prenatal 
BPA exposure decreased the latency period 
(average time to first tumor after DBMA 
treatment) by 78 days. Furthermore, mam-
mary tumors in the high-dose BPA group 
(250 µg/kg BW) were more likely than those 
in control rats to be classified as grade II 
according to the Bloom-Richardson scoring 
index, which is based on adenocarcinoma 
tubular pattern, nuclear grade, and mitotic 
index (Meyer et al. 2005).
The doses chosen for this study (25 and 
250 µg BPA/kg BW to pregnant dams) 
were based on reported human exposures, 
experimental studies in rats, and the U.S. 
Environmental Protection Agency (EPA) 
maxi  mum acceptable dose. Serum BPA con-
centrations in pregnant human females have 
been reported to be 0.46–19 µg/L (Kuroda 
et al. 2003; Schonfelder et al. 2002; Welshons 
et al. 2006). Exposure assessments have ranged 
from 0.2 µg/L (nanograms per gram of tissue) 
in human fetal cord serum up to 105 µg/L 
in human placenta (Kuroda et al. 2003). 
Within the United States, an exposure of up to   
50 µg/kg/day (50 ppb) is considered safe by 
the U.S. EPA, satisfying a 1,000-fold mar-
gin of safety (U.S. EPA 1988). Considering 
metabolism and disposition by the pregnant 
female rat and dilution to each individual fetus, 
it is calculated that each offspring would be 
exposed to 100–1,000 times less BPA than the 
treated mother. Consequently, the offspring 
of dams exposed to the high (250 µg/kg BW) 
and low (25 µg/kg BW) BPA doses would have 
been exposed to approximately 0.25–2.5 and 
0.025–0.25 µg BPA/kg BW/day, respectively 
(Kurebayashi et al. 2005; Snyder et al. 2000), 
which is less than the daily tolerable dose of 
50 µg/kg BW/day established by the U.S. EPA. 
In the present study we did not observe any 
toxic effects on body weight, vaginal opening, 
estrous cyclicity, and serum estrogen and pro-
gesterone concentrations in offspring exposed 
to either BPA dose.
So why were rats that were prenatally 
exposed to BPA more susceptible to DMBA 
carcinogenesis at PND100 than at PND50? 
Previously, we reported that prenatal treatment 
with 250 µg BPA/kg BW resulted in a sig-
nificantly increased number of terminal ducts 
at PND100 but not at PND50 (Moral et al. 
2008). Terminal end buds and terminal ducts 
are considered the most susceptible terminal 
ductal structures of the rat mammary gland 
because of the high mitotic index and undif-
ferentiated state of the cells in these structures 
(Russo and Russo 1978). Beyond that, terminal 
ductule hyperplasia is an early lesion present 
in rat mammary carcino  genesis (Haslam and 
Bern 1977; Shina and Dao 1975). Our finding 
of increased Ki-67 expression in the mammary 
ducts of 100-day-old rats after prenatal expo-
sure to BPA suggests that increased suscepti-
bility to DBMA-induced carcinogenesis is a 
possible consequence of BPA-mediated effects 
on cell proliferation. In addition, Markey 
et al. (2001) reported that mice exposed to 
250 µg BPA/kg BW/day by means of Alzet 
osmotic pumps during gestation had a sig-
nificant increase in all epithelial structures on 
PND180. Therefore, greater availability of tar-
get structures—in addition to a cellular micro-
environment favoring carcinogenesis—could 
explain the increased tumorigenesis response.
At the molecular level, our previous gene 
array studies demonstrated that prenatal 
BPA exposure significantly down-regulated 
a number of breast differentiation markers at 
PND100, including Fabp3, the homolog to 
mammary-derived growth inhibitor, a tumor 
suppressor (Hu et al. 1997; Yang et al. 1994), 
and whey acidic protein, a mammary differenti-
ation marker (Dandekar et al. 1982). Although 
it is attractive to explain cancer susceptibility 
at the gene level, this needs to be validated at 
the protein level. Using Western blot analysis, 
we found differential effects of BPA exposure 
on ER-α and SRC protein expression in the 
mammary gland. ER-α was down-regulated 
at PND50, but up-regulated at PND100 in 
high-dose BPA offspring compared with con-
trols. The expression of downstream targets of 
ER (PR-A and Bcl-2) (Henriksen et al. 2009) 
in mammary glands on PND50 and PND100 
followed an expression pattern similar to ER-α 
at each age, suggesting that increased expression 
of this receptor plays an active role in increased 
susceptibility to tumori  genic effects of DMBA 
on PND100. This is also consistent with the 
fact that DMBA-induced mammary cancer 
in rats is initially estrogen dependent (Bradley 
et al. 1976), as we would expect an increase 
in carcinogenesis with exposure to DBMA 
at PND100 versus PND50 if there is more 
ER signaling at that time. Furthermore, we 
observed that SRCs 1–3 were all up-regulated 
in BPA-exposed rats compared with controls 
at PND100, but only SRC-3 was significantly 
up-regulated at PND50. This shift in the 
expression of ER-α and the sex steroid coreg-
ulators may explain the shift in the window 
of susceptibility to DBMA-induced carcino-
genesis. Our finding of increased steroid recep-
tor coregulator expression after BPA treatment 
is not without precedent, as we have previously 
reported that prepubertal exposure to BPA 
(PND2–PND20) results in up-regulated SRCs 
1–3 at 50 days of age (Jenkins et al. 2009). 
Hence, there is commonality in expression of 
up-regulated SRCs 1–3 as well as susceptibility 
for chemically induced mammary cancer, after 
prenatal and pre  pubertal BPA exposure. 
Our results suggest a plausible mechanism 
of action by which prenatal BPA exposure 
could alter signaling molecules, which in turn 
could increase cell proliferation and contribute 
to increased susceptibility to carcinogenesis. 
First, increased levels of EGFR on PND100 
suggest the availability of more receptors to 
activate Ras (Ras-GTP) and subsequently 
Raf-1, which through a series of intermediate 
steps results in phosphorylation of the mito-
gen-activated protein kinases (MAPK) ERK 
1/2. These activated kinases then translocate 
into the nucleus where they phosphorylate 
specific transcription factors involved in cell 
prolifera  tion. Second, increased activation of 
phospho-IGF-1R on PND100 could poten-
tially induce activation of phospho-Akt as well 
as MAPK signaling pathways that promote cell 
survival by inhibiting apoptosis. Alternatively, 
EGFR can induce activation of Akt by form-
ing hetero  dimers with other members of the 
ErbB family. Akt activity is elevated in several 
types of human malignancy, including breast, 
ovarian, lung, and thyroid cancers (Vivanco 
and Sawyers 2002). Third, increased activa-
tion of phospho-ErbB2 can lead to increased 
Akt and MAPK signaling. Convergence of the 
EGFR/erbB2 and IGF-1R signaling pathways 
could contribute to increased cell prolifera-
tion on PND100 and increased susceptibility BPA shifts susceptibility for mammary cancer
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to tumorigenesis after DBMA exposure on 
PND100 and explain the lack of BPA effects 
on tumorigenesis after DBMA exposure on 
PND50, when only phospho-ErbB2, phospho-
Akt, and phospho-ERK 1/2 were increased 
in BPA-exposed animals. On the other hand, 
SRCs have been reported to directly influence 
steroid receptor action, and they have also been 
suggested as transcription factors that may 
indirectly promote steroid-mediated gene tran-
scription by increasing growth factor signal-
ing (O’Malley and Kumar 2009). In addition, 
SRCs have been shown to interact with human 
epidermal growth factor receptor 2 (HER2/
erbB2) (Bouras et al. 2001), and over  expression 
of HER2 and SRC-3 are both associated with 
a worse prognosis in cases of human breast 
cancer (Kirkegaard et al. 2007; McIlroy et al. 
2006). We found that pre  natal BPA exposure 
increased the level of ER-α and all three mem-
bers of the SRC family on PND100 in rats. 
These effects may translate to increased ER-α 
signaling and also suggest that cross-talk of 
SRCs and HER2/erbB2 could further promote 
an increase in cell proliferation on PND100 
that is not present in the mammary gland on 
PND50 when ER-α is decreased and only 
SRC-3 is increased. Future research is neces-
sary to confirm this hypothesis.
Additional research is also needed to 
determine the underlying mechanism link-
ing early exposure to BPA to long-lasting 
effects on the mature animal. The prevailing 
hypothesis is that pre  natal (or early postnatal) 
exposure to a hormonally active chemical can 
permanently alter gene expression by altering 
DNA methyla  tion or chromatin assembly 
(Ho et al. 2006; Hsu et al. 2010). Imprinting 
or organizational effects during early critical 
periods of develop  ment have been described 
that cause permanent manifestations later in 
life, even in the absence of the original effec-
tor (Baylin et al. 1998; Lamartiniere 2002; 
Lamartiniere et al. 1982). We believe that 
imprinting after exposure to BPA and other 
hormonally active chemicals can determine 
the biochemical blueprint of mammary tissue 
responses to future stimuli in adults.
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